Marit Tveito1,2, Gudrun Høiseth3,4,5, Tore Haslemo3,6, Espen Molden3,7, Robert Løvsletten Smith3. 1. Center for Psychopharmacology, Diakonhjemmet Hospital, PO Box 85, 0319, Vinderen, Oslo, Norway. marit.tveito@me.com. 2. Norwegian National Advisory Unit on Aging and Health, Vestfold Hospital Trust, Tønsberg, Norway. marit.tveito@me.com. 3. Center for Psychopharmacology, Diakonhjemmet Hospital, PO Box 85, 0319, Vinderen, Oslo, Norway. 4. Department of Forensic Sciences, Oslo University Hospital, Oslo, Norway. 5. Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 6. Department of Life Sciences and Health, Oslo Metropolitan University, Oslo, Norway. 7. Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway.
Abstract
PURPOSE: Paliperidone palmitate is an antipsychotic medication available as long-acting injectable (LAI) formulations. The aim of this study was to investigate the effect of age and gender on paliperidone exposure after administration of LAI formulations. METHODS: Data on serum concentrations of paliperidone from patients using LAI during were included retrospectively from a therapeutic drug monitoring (TDM) service. Information about dose was obtained from the requisition forms. As a measure of exposure, daily dose-adjusted serum concentration (C/D ratio) was used. Based on initial analysis of C/D ratios versus age, a breaking point close to 50 years was observed, thus deciding the grouping of patients as older (≥50 years) or younger (15-49 years). Linear mixed model analyses, allowing multiple measurements per patients, were used. RESULTS: In total, 1223 patients were included, whereof 1158 patients used paliperidone LAI in once-monthly intervals. In these patients (27.9% older), older patients had significantly higher paliperidone C/D ratio than younger patients (+20%, p<0.001). Compared to males, females had higher C/D ratio (+14%; p<0.001). Subsequently, older female users of once-monthly LAI intervals had 41% higher paliperidone C/D ratios compared to younger males (15.0 vs. 21.2 nM/mg; p<0.001). Compared to females aged 21-30 years, females with high age (≥70 years) had at least 105% higher paliperidone C/D ratio (p<0.001). CONCLUSION: The present study shows that older age and female gender are associated with higher paliperidone exposure than younger age and males, respectively. Particularly, older female patients (>50 years) are likely exposed to high concentration and cautious dosing in this subgroup is required.
PURPOSE: Paliperidone palmitate is an antipsychotic medication available as long-acting injectable (LAI) formulations. The aim of this study was to investigate the effect of age and gender on paliperidone exposure after administration of LAI formulations. METHODS: Data on serum concentrations of paliperidone from patients using LAI during were included retrospectively from a therapeutic drug monitoring (TDM) service. Information about dose was obtained from the requisition forms. As a measure of exposure, daily dose-adjusted serum concentration (C/D ratio) was used. Based on initial analysis of C/D ratios versus age, a breaking point close to 50 years was observed, thus deciding the grouping of patients as older (≥50 years) or younger (15-49 years). Linear mixed model analyses, allowing multiple measurements per patients, were used. RESULTS: In total, 1223 patients were included, whereof 1158 patients used paliperidone LAI in once-monthly intervals. In these patients (27.9% older), older patients had significantly higher paliperidone C/D ratio than younger patients (+20%, p<0.001). Compared to males, females had higher C/D ratio (+14%; p<0.001). Subsequently, older female users of once-monthly LAI intervals had 41% higher paliperidone C/D ratios compared to younger males (15.0 vs. 21.2 nM/mg; p<0.001). Compared to females aged 21-30 years, females with high age (≥70 years) had at least 105% higher paliperidone C/D ratio (p<0.001). CONCLUSION: The present study shows that older age and female gender are associated with higher paliperidone exposure than younger age and males, respectively. Particularly, older female patients (>50 years) are likely exposed to high concentration and cautious dosing in this subgroup is required.
Authors: Robert L Smith; Marit Tveito; Lennart Kyllesø; Marin M Jukic; Magnus Ingelman-Sundberg; Ole A Andreassen; Espen Molden Journal: Eur Neuropsychopharmacol Date: 2020-06-25 Impact factor: 4.600
Authors: Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao Journal: N Engl J Med Date: 2005-09-19 Impact factor: 91.245
Authors: Jari Tiihonen; Ellenor Mittendorfer-Rutz; Maila Majak; Juha Mehtälä; Fabian Hoti; Erik Jedenius; Dana Enkusson; Amy Leval; Jan Sermon; Antti Tanskanen; Heidi Taipale Journal: JAMA Psychiatry Date: 2017-07-01 Impact factor: 21.596
Authors: Stefan Leucht; Claudia Leucht; Maximilian Huhn; Anna Chaimani; Dimitris Mavridis; Bartosz Helfer; Myrto Samara; Matteo Rabaioli; Susanne Bächer; Andrea Cipriani; John R Geddes; Georgia Salanti; John M Davis Journal: Am J Psychiatry Date: 2017-05-25 Impact factor: 18.112
Authors: Hugh C Hendrie; Wanzhu Tu; Rebeka Tabbey; Christianna E Purnell; Roberta J Ambuehl; Christopher M Callahan Journal: Am J Geriatr Psychiatry Date: 2013-04-06 Impact factor: 4.105
Authors: John M Kane; Nina R Schooler; Patricia Marcy; Christoph U Correll; Eric D Achtyes; Robert D Gibbons; Delbert G Robinson Journal: JAMA Psychiatry Date: 2020-12-01 Impact factor: 21.596